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Certain microRNAs (miRNAs) targeting the molecules in the insulin
signaling cascades are dysregulated by saturated fatty acids (SFA),
which can lead to insulin resistance and type 2 diabetes. This article
reports the accompanying data collected using miRNAs microarrays
to identify the changes in miRNA expression in HepG2 cells treated
with SFA palmitate. Differentially expressed miRNA analyses in
HepG2 cells showed that a range of upregulated (41.5-fold) or
downregulated (o0.5-fold) miRNAs. Further extensive insights into
the implications of miRNAs, particularly miR-1271, in HepG2 cells can
be found in "MiR-1271 upregulated by saturated fatty acid palmitate
provokes impaired insulin signaling by repressing INSR and IRS-1
expression in HepG2 cells" (W.M. Yang, K.H. Min, W. Lee, 2016) [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biology, Biochemistry
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Value of the data
 The data highlight the biological signiﬁcance of the miRNAs involved in the pathogenesis of SFA-
induced metabolic diseases.
 These results can be compared with gene expression analysis from other cell or tissue types in
obesity.
 The differentially expressed miRNAs in this dataset could be applied in further functional studies of
the cellular and systemic phenotype changes resulting from SFA-induced obesity and metabolic
diseases.1. Data
The high dietary intake of saturated fatty acids (SFA), which is the leading cause of obesity, fre-
quently causes ectopic lipid accumulation and increase the risk of insulin resistance in non-adipose
tissues, such as the liver and skeletal muscle [2]. The expression of certain miRNAs targeting the
insulin signaling molecules is modulated aberrantly in diet-induced obesity, which participates
actively in the pathogenesis of insulin resistance [3,4]. A previous study reported that SFA palmitate
induces miR-1271 in HepG2 hepatocytes, and the expression of INSR and IRS-1 is suppressed by
targeting their 3’UTR directly [1]. This means that certain miRNA induced by SFA could be linked
causally to the development of hepatic insulin resistance and further to type 2 diabetes. This paper
reports accompanying data collected from Affymetrix GeneChip microarrays to identify the changes
in miRNA expression in HepG2 cells treated with SFA palmitate. Differentially expressed microRNA
analyses in HepG2 cells (Supplementary File. 1) revealed a range of miRNAs upregulated more than
1.5-fold (Supplementary File. 2) or downregulated less than 0.5-fold (Supplementary File. 3). Among
those differentially expressed miRNAs, upregulated miRNAs have implications on the reduction of
INSR and IRS-1 observed in palmitate-treated HepG2 cells [1]. Further analysis of the data and
insights into the implications of miRNAs, especially miR-1271, in HepG2 cells are reported in another
publication [1].2. Experimental design, materials and methods
2.1. Cells and palmitate treatment
HepG2, a human liver cancer cell line, was purchased from ATCC (#77400). The HepG2 cells were
grown in MEMα supplemented with 10% FBS and 1% penicillin-streptomycin (Gibco) in an atmo-
sphere containing 5% CO2 at 37 °C. The cells from passages 3–10 were used for the following
experiments. A fatty acid-free bovine serum albumin (BSA, Bovogen, VIC, Australia)-conjugated pal-
mitate (Sigma-Aldrich) solution was prepared, as described previously [5]. Brieﬂy, BSA and sodium
palmitate were dissolved completely in 150 mM NaCl by heating at 37 °C and 70 °C, respectively. The
BSA solution was added dropwise to the palmitate solution at 37 °C with continuous stirring until the
W.-M. Yang et al. / Data in Brief 9 (2016) 996–999998palmitate to BSA molar ratio was 6:1. The BSA-conjugated palmitate and BSA vehicle was aliquoted
and stored at 80 °C. The HepG2 cells were seeded at a density of 5105/well in a six-well plate. On
the next day, the cells were treated with BSA-conjugated palmitate (0.5 mM) for 0–18 h. The control
cells were treated with the BSA vehicle. Where applicable, the cells were treated with or without
100 nM insulin during the ﬁnal 30 min of incubation.
2.2. RNA extraction and quality check
The total RNA from the HepG2 cells was extracted using a miRNeasy Mini Kit (Qiagen) according to
the manufacturer's instructions. The purity and integrity of the RNA were assessed using a ND-1000
Spectrophotometer (NanoDrop) and Agilent 2100 Bioanalyzer (Agilent Technologies). Equal amounts
of RNA from ﬁve mice were pooled together and used for the microarray.
2.3. miRNA arrays analysis
The total RNA described above was prepared and subjected to an Affymetrix Genechip miRNA
4.0 array (Affymetrix, Santa Clara, CA, USA) process according to the Affymetrix technical instructions.
Brieﬂy, 600 ng RNA was labeled with a FlashTag™ Biotin RNA Labeling Kit (Genisphere, Hatﬁeld, PA,
USA). The labeled RNA was quantiﬁed, fractionated, and hybridized to the miRNA microarray
according to the manufacturer's instructions. The labeled RNA was heated to 99 °C for 5 min and
incubated at 45 °C for 5 min. RNA-array hybridization was conducted with agitation at 60 rpm for
16 h at 48 °C on an Affymetrix
s
450 Fluidics Station. The chips were stained on a Genechip Fluidics
Station 450 (Affymetrix), and scanned using an Affymetrix GCS 3000 scanner (Affymetrix). All signals
were normalized according to the quantile method after a log 2 transformation to make them
comparable across microarrays.Acknowledgements
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